Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly

Anti-Cancer Drugs

Volumn 14, Issue 1, 2003, Pages 13-19

  Wang, Jieyi ^a   Lou, Pingping ^a   Lesniewski, Rick ^a   Henkin, Jack ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Angiogenesis; Endothelial cell; Paclitaxel; Taxol

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL;

ANGIOGENESIS; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL CYCLE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LOW DRUG DOSE; MICROTUBULE; MICROTUBULE ASSEMBLY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; SPECIES DIFFERENCE;

ANIMALS; CELL DIVISION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH INHIBITORS; HUMANS; MICE; MICROTUBULES; NEOVASCULARIZATION, PHYSIOLOGIC; PACLITAXEL;

EID: 0037268220     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200301000-00003     Document Type: Article

References (19)

1. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333:1757-1163.
2. Kerbel RS. Tumor angiogenesis: past, present, and the near future. Carcinogenesis 2000; 21:505-515.
3. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990; 348:555-557.
4. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284:808-812.
5. Kerbel RS, Viloria-Petit A, Klement G, Rak J. 'Accidental' anti-angiogenic drugs, anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000; 36:1248-1257.
6. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991; 27A:482-487.
7. Schirner M. Antiangiogenic chemotherapeutic agents. Cancer Metast Rev 2000; 19:67-73.
8. Browder T, Butterfield CE, Kraling BM, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-1886.
9. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105:R15-R24.
10. Wang J, Lou P, Henkin J. Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem 2000; 77:465-473.
11. Kifle L, Dickinson R, Okasinski G, Fry D. Construction of human endothelial cell lines expressing cell adhesion molecule promoter//uc reporter genes. FASEB J 1996; 10:A625.
12. Montesano R, Pepper MS, Mohle-Steinlein U, Risau W, Wagner ET, Ordi L. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 1990; 62:435-445.
13. Nehls V, Drenckhahn D. A novel, microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis. Microvasc Res 1995; 50:311-322.
14. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90:9552-9556.
15. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 1991; 13:31-36.
16. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2:1843-1849.
17. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57:81-86.
18. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999; 14:31-36.
19. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59:3374-3378.